|
1) 井上郁夫. エゼチミブによる食後高脂血症の管理とそのEBM. Mebio. 2007; 24: 142-62
|
|
|
|
2) Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1-like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303: 1201-4
|
|
|
|
|
3) Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1-like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007; 14: 99-108
|
|
|
|
|
4) Levy E, Spahis S, Sinnett D, et al. Intestinal cholesterol transport proteins: an update and beyond. Curr Opin Lipidol. 2007; 18: 310-8
|
|
|
|
|
|
5) Wang DQ. Regulation of intestinal cholesterol absorption. Annu Rev Physiol. 2007; 69: 221-48
|
|
|
|
|
|
6) 井上郁夫. 核内受容体PPARs, LXRと脂質代謝. Medicina. 2007; 44: 1558-65
|
|
|
|
|
7) Chen W, Chen G, Head DL, et al. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007; 5: 73-9
|
|
|
|
|
|
8) 井上郁夫. コレステロール吸収阻害薬(レジンとエゼチマイブ). Mebio. 2006; 23: 118-31
|
|
|
|
|
|
9) Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007; 117: 1968-78
|
|
|
|
|
|
10) Miettinen TA, Gylling H, Lindbohm N, et al. Finnish Treat-to-Target Study Investigators. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med. 2003; 141: 131-7
|
|
|
|
|
|
11) Miettinen TA, Gylling H, Strandberg T, et al. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ. 1998; 316: 1127-30
|
|
|
|
|
|
12) Strandberg TE, Tilvis RS, Pitkala KH, et al. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol. 2006; 48: 708-14
|
|
|
|
|
|
13) Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002; 106: 1943-8
|
|
|
|
|
|
14) Davidson MH, Ballantyne CM, Kerzner B, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004; 58: 746-55
|
|
|
|
|
|
15) Goldberg AC, Sapre A, Liu J, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004; 79: 620-9
|
|
|
|
|
|
16) Ballantyne CM, Houri J, Notarbartolo A, et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003; 107: 2409-15
|
|
|
|
|
|
17) Stein EA, Ballantyne CM, Engelhardt M, et al. Treating patients with a prior history of statin related muscle side effects to LDL-C goals using fluvastatin XL alone, or in combination with ezetimibe: A randomized, double-blind multicentre study. ESC Congress 2007, 1-5 September, Vienna, Austria
|
|
|
|
|
|
18) Catapano AL, Ballantyne CM, Davidson MH, et al. Evaluation of ezetimibe/simvastatin vervus rosuvastatin in hypercholesterolmic pastients with type 2 diabetes or metabolic syndrome. 42th EASD 2006, 14-17 September, Copenhargen, Demmark
|
|
|
|
|
|
19) Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007; 23: 1169-76
|
|
|
|
|
|
20) Farnier M, Freeman MW, Macdonell G, et al; The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005; 26: 897-905
|
|
|
|
|
|
21) McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006; 47: 1584-7
|
|
|
|
|
|
22) Ishii J, Inoue I. Measures to meet the side effects of the orally administered antihyperglycemic drugs. Nippon Rinsho. 1997; 55 Suppl: 104-13
|
|
|
|
|
|
23) Inoue I. The drug treatment for hyperlipidemic patient with diabetes mellitus-pharmacology based medicine and pathogenesis based medicine. Nippon Rinsho. 2007; 65 Suppl 7: 386-406
|
|
|
|
|